StreetInsider.com News Articles

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

Thu, 25 Jun 2026 08:30:00 -0400

TOKYO--(BUSINESS WIRE)-- Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale

Asahi Kasei Corp. (3407:JP) (AHKSY) PT Raised to JPY1,740 at Nomura/Instinet

Mon, 22 Jun 2026 06:54:06 -0400
Nomura/Instinet analyst Shigeki Okazaki raised the price target on Asahi Kasei Corp. (3407:JP) (OTC: AHKSY) to JPY1,740.00 (from JPY1,700.00) while maintaining a Neutral rating.

Asahi Kasei Corp. (3407:JP) (AHKSY) PT Raised to JPY1,740 at Nomura/Instinet

Mon, 22 Jun 2026 06:54:06 -0400
Nomura/Instinet analyst Shigeki Okazaki raised the price target on Asahi Kasei Corp. (3407:JP) (OTC: AHKSY) to JPY1,740.00 (from JPY1,700.00) while maintaining a Neutral rating.

Asahi Kasei Corp. (3407:JP) (AHKSY) PT Raised to JPY1,740 at Nomura/Instinet

Mon, 22 Jun 2026 06:54:06 -0400
Nomura/Instinet analyst Shigeki Okazaki raised the price target on Asahi Kasei Corp. (3407:JP) (OTC: AHKSY) to JPY1,740.00 (from JPY1,700.00) while maintaining a Neutral rating.

Asahi Kasei Corp. (3407:JP) (AHKSY) PT Raised to JPY1,740 at Nomura/Instinet

Mon, 22 Jun 2026 06:54:06 -0400
Nomura/Instinet analyst Shigeki Okazaki raised the price target on Asahi Kasei Corp. (3407:JP) (OTC: AHKSY) to JPY1,740.00 (from JPY1,700.00) while maintaining a Neutral rating.

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Wed, 17 Jun 2026 08:00:00 -0400

CARY, N.C., June 17, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc analysis of a Phase 3b trial. Additionally, there will be a presentation on a

EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei’s Novel Electrolyte Acetolyte™

Tue, 02 Jun 2026 08:30:00 -0400

DUSSELDORF, Germany--(BUSINESS WIRE)-- German battery manufacturer EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell, initially launched in March 2026. The cell incorporates Asahi Kasei’s novel acetonitrile-containing electrolyte Acetolyte™, whose high ionic conductivity reduces internal resistance and improves rate capability, especially under demanding temperature conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602935724/en/
EAS ultra-high-power lithium-ion cell
In November 2025, Asahi Kasei signed a licensing agreement with EAS Batteries covering the use of its electrolyte in the German